DGNS low risk high potential CL 236
TP1 278
TP2 430
please DYOR
DGNS potentially to the moon since its already takes sometimes for consolidation period.
−4 IDR
−13.66 B IDR
145.70 B IDR
250.00 M
About DIAGNOS LABORATORIUM UTAMA TBK
Sector
Industry
CEO
Mesha Rizal Sini
Website
Headquarters
Jakarta
Founded
2007
ISIN
ID1000158702
FIGI
BBG00YJ4QPJ2
PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. Its products include clinical pathology laboratory, anatomy pathology laboratory, and genomics laboratory. Its services include home care health tests, corporate health tests, and Covid-19 tests. The company was founded on August 29, 2007 and is headquartered in Jakarta, Indonesia.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DGNS is 198 IDR — it has decreased by −1.00% in the past 24 hours. Watch DIAGNOS LABORATORIUM UTAMA TBK stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on IDX exchange DIAGNOS LABORATORIUM UTAMA TBK stocks are traded under the ticker DGNS.
DGNS stock has fallen by −9.17% compared to the previous week, the month change is a −16.10% fall, over the last year DIAGNOS LABORATORIUM UTAMA TBK has showed a −23.85% decrease.
DGNS reached its all-time high on Jul 5, 2021 with the price of 1,485 IDR, and its all-time low was 160 IDR and was reached on Aug 21, 2023. View more price dynamics on DGNS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DGNS stock is 5.58% volatile and has beta coefficient of 0.72. Track DIAGNOS LABORATORIUM UTAMA TBK stock price on the chart and check out the list of the most volatile stocks — is DIAGNOS LABORATORIUM UTAMA TBK there?
Today DIAGNOS LABORATORIUM UTAMA TBK has the market capitalization of 247.50 B, it has decreased by −7.27% over the last week.
Yes, you can track DIAGNOS LABORATORIUM UTAMA TBK financials in yearly and quarterly reports right on TradingView.
DGNS net income for the last quarter is 940.04 M IDR, while the quarter before that showed 217.84 M IDR of net income which accounts for 331.52% change. Track more DIAGNOS LABORATORIUM UTAMA TBK financial stats to get the full picture.
As of Dec 22, 2024, the company has 64.00 employees. See our rating of the largest employees — is DIAGNOS LABORATORIUM UTAMA TBK on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DIAGNOS LABORATORIUM UTAMA TBK EBITDA is 9.33 B IDR, and current EBITDA margin is 0.41%. See more stats in DIAGNOS LABORATORIUM UTAMA TBK financial statements.
Like other stocks, DGNS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DIAGNOS LABORATORIUM UTAMA TBK stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DIAGNOS LABORATORIUM UTAMA TBK technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DIAGNOS LABORATORIUM UTAMA TBK stock shows the sell signal. See more of DIAGNOS LABORATORIUM UTAMA TBK technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.